Bone Gelatin Pharma Grade API is a purified protein obtained from demineralized bovine bone collagen through controlled alkaline liming, aqueous extraction, filtration, deionization, and drying. The product is supplied as free-flowing granules or powder in 20/40/60/80 mesh fractions. Representative model designations encode source, gel strength, and mesh cut: oral grades include BG-O-120, BG-O-180, and BG-O-220, while injectable grades include BG-I-150 and BG-I-200. The material conforms to the USP-NF Gelatin monograph and the European Pharmacopoeia Gelatin monograph where applicable. It is supplied for hard capsule shell manufacture, tablet granulation, granule formation, oral liquids, and injectable formulations after appropriate dissolution and terminal filtration.

Bone gelatin of this class differs from food-grade and technical-grade bone glue in residual ash, endotoxin, microbial, and molecular weight controls. Pharmaceutical-grade material requires sulfated ash ≤2.0% for oral use and ≤0.5% for injectable use, loss on drying ≤12.0%, and bacterial endotoxins ≤2.5 EU/mg for oral use and ≤0.1 EU/mg for injectable use as measured by USP <85> and Ph. Eur. 2.6.14. These limits are not interchangeable with technical-grade ossein or bone glue, which is typically sold without endotoxin certification or residue-on-ignition control.

What Pharmacopoeial Limits Define Bone Gelatin API for Oral and Injectable Dosage Forms?

Gel strength is determined at 6.67% w/w after 17 h at 10°C using a 12.7 mm plunger and a Bloom gelometer. Oral grades are routinely specified at 120–220 Bloom, while injectable grades are controlled at 150–220 Bloom because higher gel strength correlates with a higher molecular weight fraction above 100 kDa. Viscosity is measured at 60°C on a 6.67% solution by USP <911> capillary viscometry; typical values are 3.0–5.0 mPa·s for oral grades and 2.0–4.0 mPa·s for injectable grades. pH of a 1% solution is controlled to 4.5–6.5 depending on the extraction process. Residue on ignition is performed by USP <281>. Elemental impurities are managed through ICH Q3D risk assessment, with lead, cadmium, arsenic, and mercury monitored below 1 ppm, 0.5 ppm, 1 ppm, and 0.5 ppm respectively.

Microbial enumeration, absence of Salmonella and Escherichia coli, and mold/yeast below 100 CFU/g are verified by USP <61> and USP <62>. The powder is supplied in low-endotoxin packaging; injectable grades are double polyethylene-in-aluminum laminate bags after 0.2 μm filtration and controlled drying.

Gel Strength, Viscosity, and Endotoxin Load as Control Parameters

Thermal degradation during extraction is the central process conflict. Collagen hydrolysis above 75°C increases the low-molecular-weight peptide fraction below 50 kDa, reducing Bloom strength and increasing foam stability in capsule solutions. In a triple-extraction battery, the first extract is typically drawn at 55–65°C and the second at 65–75°C; the third extract is reserved for technical grades because its gel strength falls below 100 Bloom. Continuous monitoring of retentate viscosity at 60°C is used to terminate extraction when viscosity falls below 2.5 mPa·s. If viscosity exceeds 5.5 mPa·s, capsule pinning solutions become difficult to transfer at 55°C because gelation onset occurs at 23–28°C; insulated jacketed lines with 55–60°C water are required. Conversely, if viscosity falls below 2.8 mPa·s, dried capsule films show reduced tensile strength and shell body wall thickness must be increased beyond 0.15 mm to avoid breakage on high-speed capsule filling machines operating at 120,000 capsules/hour.

Endotoxin load is controlled by acid demineralization, alkaline liming at pH ≥12.5 for 20–60 days, and pasteurization of bone material; injectable grades receive additional depth filtration and 0.2 μm membrane filtration. A processing temperature above 80°C for more than 2 h during concentration under vacuum can reduce Bloom strength by 10–20%, as measured by comparative gel strength before and after evaporation.

Injectable-grade bone gelatin is manufactured under cleanroom conditions consistent with ISO 14644 Class 8 or better, with bacterial endotoxin ≤0.1 EU/mg, bioburden ≤10 CFU/g, and moisture ≤10.0%. The source material is limited to category 3 animal by-products under Regulation (EC) No 1069/2009; skull and spinal cord are excluded. Viral and TSE risk is assessed under Ph. Eur. 5.1.7 principles. Alkaline liming at pH ≥12.5 for 20–60 days, filtration through diatomaceous earth, and terminal 0.22 μm filtration are applied to reduce prion and viral load. Unmodified injectable-grade gelatin is used as a stabilizer or viscosity donor in parenteral solutions at 1–5% w/v; succinylated bone gelatin derivatives intended for plasma volume expansion are controlled for molecular weight distribution 23–30 kDa weight-average and osmolarity after succinylation. Autoclaving a 4% gelatin solution at 121°C for 15 min reduces Bloom strength by 10–15% but does not compromise the colloid osmotic effect if the molecular weight fraction above 30 kDa remains above 60%.

Moisture protection in capsule shells requires pre-drying at 40°C when storage RH exceeds 60%.

When Tablet Granulation Requires Low-Viscosity Bone Gelatin Rather Than Hide-Derived 250 Bloom Material

In tablet binder applications, 100–150 Bloom bone gelatin with viscosity 3.0–3.5 mPa·s is preferred over 250 Bloom hide gelatin because lower molecular weight improves spray atomization and reduces wet mass tack. A 5–10% w/w aqueous solution held at 45–50°C is sprayed through a 1.0 mm nozzle at 1.8–2.2 bar in a top-spray fluid bed. At this viscosity, nozzle blockage is less frequent than with hide gelatin at equal Bloom, and granule growth follows a controlled saturation profile. Bone gelatin binder at 2.0–5.0% w/w dry solids increases tablet hardness by 20–30% over starch paste at equal binder level and typically maintains disintegration time below 15 min in USP <701> apparatus when tablet hardness is 60–90 N. Overgranulation can be detected by an increase in impeller torque of 8–12%; if the wet mass temperature falls below 30°C, gelation raises viscosity abruptly and the granule size distribution shifts toward oversize agglomerates above 2.0 mm. The binder solution should not be combined with formaldehyde or glutaraldehyde because crosslinking produces insoluble films and delays disintegration beyond 30 min.

Bone Gelatin versus Porcine, Fish, and Hide Gelatin under Identical Bloom Conditions

At 200 Bloom, bone gelatin exhibits a gelation temperature of 23–28°C and a melting temperature of 30–35°C at 6.67% w/w, whereas cold-water fish gelatin typically shows gelation at 8–15°C and melting at 20–25°C. This difference makes fish gelatin unsuitable for capsule shells exposed to ambient storage above 25°C, while bone gelatin maintains shell dimensions up to 35°C at 40% RH. Porcine skin gelatin and bovine hide gelatin can reach similar Bloom values, but bone gelatin from limed extraction contains lower ammoniacal nitrogen, typically <0.2% versus <0.5% for some hide gelatins, which improves clarity and reduces odor. Bone gelatin also has a higher natural mineral residue; complete demineralization with 3–6% v/v hydrochloric acid is required to achieve residue on ignition ≤2.0%. In capsule shell production, hide gelatin 250 Bloom may produce a stiffer gel at high solids, but the higher viscosity at 55°C requires more vacuum deaeration and can slow pin dipping. Bone gelatin at 200–220 Bloom provides a process window between 55°C and 60°C that suits stainless steel pin lines.

Capsule shell lines using 30–35% w/w bone gelatin solution at 55–60°C require vacuum deaeration at −0.08 MPa to remove air bubbles. Pin dipping is performed at 25–30°C with dew point ≤20°C; shell body wall thickness 0.10–0.15 mm is controlled by solution viscosity and withdrawal speed. Drying tunnels are staged at 22–28% RH and 30–40°C. Capsule hardness and dissolution are verified by USP <711> basket method at 75 rpm; typical shell dissolution time is 2–5 min in purified water at 37°C. For granule manufacture, 120–150 Bloom bone gelatin is dry-blended at 1–5% w/w before moisture granulation or roller compaction. The binder reduces the fine fraction below 15% as measured by sieve analysis according to USP <786>. If the powder is exposed to RH >60%, pre-drying at 40°C for 4–8 h is required before gravimetric charging. The material is incompatible with strong oxidizers, formaldehyde, and tannins; these agents induce crosslinking and increase disintegration time.